Launch of CRO services specializing in regenerative medicine products
First written in FY2016. 11 of 13 entries say "Restated". Latest entry: FY2024.
No other company in this theme has enough history to compare yet.
- FY2024RestatedAnnual report
「Under the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices, we provide CDMO and CRO services specialising in regenerative medicine products to academic institutions conducting clinical research aimed at obtaining approval for regenerative medicine products, medical institutions conducting investigator-initiated clinical trials, and companies developing regenerative medicine products.」
The company continues to provide CDMO and CRO services specialising in regenerative medicine products for academic institutions, medical institutions, and companies. - FY2023-Q2RestatedAnnual report
「Under the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices, we provide CDMO and CRO services specialising in regenerative medicine products to academic institutions conducting clinical research aimed at obtaining approval for regenerative medicine products, medical institutions conducting investigator-initiated clinical trials, and companies developing regenerative medicine products.」
The company continues to provide CDMO and CRO services specialising in regenerative medicine products for academic institutions, medical institutions, and companies. - FY2023-Q1RestatedAnnual report
「Under the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices, we provide CDMO and CRO services specialising in regenerative medicine products to academic institutions conducting clinical research aimed at obtaining approval for regenerative medicine products, medical institutions conducting investigator-initiated clinical trials, and companies developing regenerative medicine products.」
The company continues to provide CDMO and CRO services specialising in regenerative medicine products for academic institutions, medical institutions, and companies. - FY2022-Q1RestatedAnnual report
「Under the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices, we provide CDMO and CRO services specialising in regenerative medicine products to academic institutions conducting clinical research aimed at obtaining approval for regenerative medicine products, medical institutions conducting investigator-initiated clinical trials, and companies developing regenerative medicine products.」
The company continues to provide CDMO and CRO services specialising in regenerative medicine products for academic institutions, medical institutions, and companies. - FY2021-Q2RestatedAnnual report
「Under the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices, we provide CDMO and CRO services specialising in regenerative medicine products to academic institutions conducting clinical research aimed at obtaining approval for regenerative medicine products, medical institutions conducting investigator-initiated clinical trials, and companies developing regenerative medicine products.」
The company continues to provide CDMO and CRO services specialising in regenerative medicine products for academic institutions, medical institutions, and companies. - FY2020RestatedAnnual report
「We provide CDMO and CRO services specialising in regenerative medicine products.」
The company continues to provide CDMO and CRO services specialising in regenerative medicine products for academic institutions, medical institutions, and companies. - FY2020-Q3RestatedAnnual report
「Under the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices, we provide CDMO and CRO services specialising in regenerative medicine products to academic institutions conducting clinical research aimed at obtaining approval for regenerative medicine products, medical institutions conducting investigator-initiated clinical trials, and companies developing regenerative medicine products.」
The company continues to provide CDMO and CRO services specialising in regenerative medicine products for academic institutions, medical institutions, and companies. - FY2020-Q2RestatedAnnual report
「Under the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices, we provide CDMO and CRO services specialising in regenerative medicine products to academic institutions conducting clinical research aimed at obtaining approval for regenerative medicine products, medical institutions conducting investigator-initiated clinical trials, and companies developing regenerative medicine products.」
The company continues to provide CDMO and CRO services specialising in regenerative medicine products for academic institutions, medical institutions, and companies. - FY2019-Q2RestatedAnnual report
「Under the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices, we provide CDMO and CRO services specialising in regenerative medicine products to academic institutions conducting clinical research aimed at obtaining approval for regenerative medicine products, medical institutions conducting investigator-initiated clinical trials, and companies developing regenerative medicine products.」
The company continues to provide CDMO and CRO services specialising in regenerative medicine products for academic institutions, medical institutions, and companies. - FY2018-Q3RestatedAnnual report
「Under the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices, we provide CDMO and CRO services specialising in regenerative medicine products to academic institutions conducting clinical research aimed at obtaining approval for regenerative medicine products and medical institutions conducting investigator-initiated clinical trials.」
The company continues to provide a CRO service specialising in regenerative medicine products together with its CDMO service. - FY2018-Q2RestatedAnnual report
「Under the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices, we provide CDMO and CRO services specialising in regenerative medicine products to academic institutions conducting clinical research aimed at obtaining approval for regenerative medicine products and medical institutions conducting investigator-initiated clinical trials.」
The company continues to provide CDMO and CRO services specialising in regenerative medicine products. - FY2017-Q1AchievedAnnual report
「In April 2016, we launched a new business under the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices, providing a CRO service specialising in regenerative medicine products to all companies conducting clinical trials for their approval and medical institutions conducting investigator-initiated clinical trials.」
The CRO business specialising in regenerative medicine products, which had been scheduled to begin in the previous fiscal year, was confirmed to have launched in April 2016. - FY2016First statedAnnual report
「In March 2016, we decided to launch a new business, a CRO service specialising in regenerative medicine products. From April 2016 onward, we will provide companies conducting clinical trials for the approval of regenerative medicine products and medical institutions conducting investigator-initiated clinical trials with comprehensive clinical development support, from pretrial consulting through regulatory approval applications.」
The service was scheduled to begin in April 2016 or later, providing comprehensive support from pretrial consulting through regulatory approval applications.